ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Arcutis Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $4.01B | $197.05M |
| Enterprise Value | $3.88B | $106.56M |
| PE Ratio | 144.96 | 20.52 |
| PS Ratio | 8.64 | 3.93 |
| PB Ratio | 18.17 | 2.14 |
| P/TBV Ratio | 19.37 | 2.46 |
| P/FCF Ratio | 102.38 | 18.25 |
| P/OCF Ratio | 101.97 | 13.78 |
Enterprise value
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| EV / Sales | 8.36 | 2.69 |
| EV / EBITDA | 113.24 | 14.86 |
| EV / EBIT | 113.24 | 19.00 |
| EV / FCF | 99.07 | 21.02 |
Income (trailing twelve months)
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Revenue | $463.98M | $57.94M |
| Gross Profit | $422.89M | $90.47M |
| Operating Income | $34.25M | -$21.44M |
| Net Income | $28.52M | -$22.46M |
| EBITDA | $34.25M | -$16.91M |
| EPS (Diluted) | $0.22 | -$0.83 |
Margins
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Gross Margin | 91.1% | 52.3% |
| Operating Margin | 7.38% | -44.5% |
| Profit Margin | 6.15% | -39.2% |
| EBITDA Margin | 7.38% | -31.3% |
| FCF Margin | 8.44% | -8.85% |
Returns
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 15.9% | -53.1% |
| Return on Assets (ROA) | 6.78% | -41.0% |
| Return on Invested Capital (ROIC) | 36.9% | -32.0% |
| Return on Capital Employed (ROCE) | 10.4% | -37.8% |
Growth
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 76.1% | 6.01% |
| Revenue Growth (3Y CAGR) | 367.3% | 2.25% |
Balance sheet
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $238.55M | $62.42M |
| Total Debt | $108.90M | $120.13M |
| Net Cash (Debt) | $129.65M | $15.68M |
| Net Cash Per Share | $1.03 | $0.65 |
| Equity (Book Value) | $220.58M | $48.79M |
| Book Value Per Share | $1.75 | $1.36 |
| Tangible Book Value | $206.89M | $23.06M |
| Working Capital | $307.33M | $75.77M |
Financial position
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.92 | 3.30 |
| Quick Ratio | 2.46 | 2.39 |
| Debt / Equity | 0.49 | 0.51 |
| Debt / EBITDA | 3.18 | 3.35 |
| Debt / FCF | 2.78 | 5.05 |
| Net Debt / EBITDA | -3.79 | 2.22 |
| Interest Coverage | 2.47 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $39.31M | -$12.35M |
| Capital Expenditures | -$158.00K | -$1.06M |
| Free Cash Flow | $39.15M | -$20.28M |
| FCF Per Share | $0.31 | -$0.41 |
Efficiency
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 1.10 | 0.38 |
| Inventory Turnover | 1.49 | 2.67 |
| Revenue Per Employee | $1.31M | $398.96K |
| Profits Per Employee | $80.56K | -$732.08K |
| Employee Count | 354 | 73 |
Dividends and yields
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | 0.71% | -21.2% |
| FCF Yield | 0.98% | -7.64% |
Shares
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 125,692,000 | 59,128,900 |
| Shares Change (YoY) | 5.53% | 11.1% |
| Shares Change (QoQ) | 0.44% | 0.54% |
| Float | 114,038,000 | 48,744,500 |
| Shares Held by Insiders | 9.27% | 11.8% |
| Shares Held by Institutions | 104.6% | 59.4% |
Taxes
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Income Tax | $779.00K | $91.50K |
Scores
| Measure | Arcutis Biotherapeutics | Industry median |
|---|---|---|
| Graham Number | $2.95 | $17.36 |
| Graham Upside | -90.8% | -45.5% |
| Altman Z-Score | 7.66 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Arcutis Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.